(Q38211580)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24825142%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

title

An insight into JAK-STAT signalling in dermatology (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24825142%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24825142%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

author name string

J A Palanivel

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24825142%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

A E Macbeth

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24825142%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

N C Chetty

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24825142%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

publication date

1 June 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24825142%20AND%20SRC:MED&resulttype=core&format=json

Clinical and Experimental Dermatology

18 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24825142%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

volume

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24825142%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24825142%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

page(s)

513-518

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24825142%20AND%20SRC:MED&resulttype=core&format=json

The JAK/STAT signaling pathway

18 March 2020

cites work

1 reference

Signaling through the JAK/STAT pathway, recent advances and future challenges

21 January 2018

1 reference

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

Characterisation of a dendritic cell subset in synovial tissue which strongly expresses Jak/STAT transcription factors from patients with rheumatoid arthritis

21 January 2018

1 reference

Analysis of JAK2 and STAT3 polymorphisms in patients with ankylosing spondylitis in Chinese Han population

21 January 2018

1 reference

Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population.

21 January 2018

1 reference

Investigation of Crohn's disease risk loci in ulcerative colitis further defines their molecular relationship

21 January 2018

1 reference

Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases

21 January 2018

1 reference

Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells

21 January 2018

1 reference

8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells

21 January 2018

1 reference

Jaks and STATs: biological implications

21 January 2018

1 reference

JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice.

21 January 2018

1 reference

Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus

21 January 2018

1 reference

Pyoderma gangrenosum in association with Janus kinase 2 (JAK2V617F) mutation.

21 January 2018

1 reference

STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma

21 January 2018

1 reference

Incyte comes of age with JAK inhibitor approval.

21 January 2018

1 reference

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

21 January 2018

1 reference

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.

21 January 2018

1 reference

A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.

21 January 2018

1 reference

Cucurbitacin I inhibits Stat3 and induces apoptosis in Sézary cells

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/CED.12273

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24825142%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference